ArticleFrontiers in public health2025
A comparative analysis of COVID-19 seroprevalence rates, observed infection rates, and infection-related mortality.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Objectives: The COVID-19 pandemic highlighted the need for data-driven decision making in managing public health crises. This study aims to extend previous research by incorporating infection-related mortality (IRM) to evaluate the discrepancies between seroprevalence data and infection rates reported to the Centers for Disease Control and Prevention (CDC), and to assess the implications for public health policy. Study design: We conducted a comparative analysis of seroprevalence data collected as part of an NIH study and CDC-reported infection rates across ten U.S. regions, focusing on their correlation with IRM calculations. Methods: The analysis includes a revision of prior estimates of IRM using updated seroprevalence rates. Correlations were calculated and their statistical relevance assessed. Results: Findings indicate that COVID-19 is approximately 2.7 times more prevalent than what CDC infection data suggest. Utilizing the lower CDC-reported rates to calculate IRM leads to a significant overestimation by a factor of 2.7. When both seroprevalence and CDC infection data are combined, the overestimation of IRM increases to a factor of 3.79. Conclusion: The study highlights the importance of integrating multiple data dimensions to accurately understand and manage public health emergencies. The results suggest that public health agencies should enhance their capacity for collecting and analyzing seroprevalence data regularly, given its stronger correlation with IRM than other estimates. This approach will better inform policy decisions and direct effective interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.